alisertib,paclitaxel
puma,spdr s&p biotech,ishares biotechnology
['alisertib', 'biomarker', 'breast', 'paclitaxel', '$ibb', '$xbi', 'puma', '$pbyi']
$pbyi puma biotechnology presents biomarker findings from phase ii study of alisertib with paclitaxel in metastatic or locally recurrent breast cancer at 2023 asco annual meeting more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt